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Before the introduction of novel molecularly targeted ther-apies, results with a wide range of chemotherapy regi-
mens for patients with advanced non-small cell lung cancer
(NSCLC) had reached a plateau beyond which improved
efficacy seemed unlikely.
Multiple trials over the last several years have demon-
strated the generally equivalent efficacy of a number of
doublet chemotherapy regimens for first-line treatment of
advanced/metastatic NSCLC. Results reported by the Eastern
Cooperative Oncology Group (ECOG) 1594 study1 and other
randomized phase 3 trials of various doublets2,3 demonstrated
different toxicities with a remarkably similar efficacy and
reproducible median survival results in the 8- to 10-month
range and 1-year survival rates of approximately 30–40%.
Docetaxel was the first agent approved by the United
States Food and Drug Administration for patients with pre-
viously treated NSCLC. This decision was based on results of
2 randomized phase 3 trials, one comparing every-3-week
docetaxel vs supportive care alone,4 and the other comparing
docetaxel with single-agent vinorelbine or ifosfamide.5 Both
of these trials demonstrated a response rate for all treatments
of 11% or less, no change in median survival for docetaxel,
but a significant benefit in 1-year survival. A subsequent large
phase 3 trial6 compared docetaxel with pemetrexed as sec-
ond-line treatment, with results revealing that both agents
were associated with an identical response rate of approxi-
mately 9% and 1-year survival of approximately 30%. The
hematologic toxicity profile of pemetrexed was superior in
terms of risk for febrile neutropenia and need for blood
product support, as well as risk of hospitalizations. Conse-
quently, pemetrexed was approved by the Food and Drug
Administration as an additional option for salvage therapy in
advanced NSCLC.
However, in the last several years, new therapies tar-
geting angiogenesis and the epidermal growth factor receptor
(EGFR) axis have demonstrated survival benefits in prospec-
tive, randomized, phase 3 clinical trials. These studies have
established bevacizumab and erlotinib as agents with an
emerging role in the treatment of many patients with ad-
vanced NSCLC.
In light of the encouraging results achieved with EGFR
tyrosine kinase inhibitors (TKIs) and other targeted ap-
proaches in the salvage setting, multiple prospective random-
ized clinical trials have tested platinum-based doublet che-
motherapy with or without a novel targeted approach, seeking
a statistically and clinically significant survival benefit. Sev-
eral novel treatment approaches have generated negative
results compared with standard doublet chemotherapy alone.
Among these, four trials of more than 1000 previously un-
treated patients each evaluated gefitinib7,8 or erlotinib9,10
versus placebo, concurrently with standard doublet chemo-
therapy of carboplatin/paclitaxel or cisplatin/gemcitabine for
up to six cycles. This was followed by maintenance therapy
with the EGFR TKI for patients who did not experience
disease progression after the planned first-line chemotherapy.
Although both the EGFR TKI and chemotherapy combina-
tions varied, the results of these trials have been consistent,
clearly demonstrating no benefit in response rate, median
survival, or overall survival from targeted therapy with either
gefitinib or erlotinib administered concurrently with doublet
chemotherapy. A subset analysis from the TRIBUTE trial10
of carboplatin/paclitaxel with erlotinib or placebo as first-line
therapy demonstrated significantly superior progression-free
and overall survival in never-smokers who received the TKI.
Several clinical trials have demonstrated that mutations
in the EGFR TK domain—generally observed in 5–20% of
tumors in patients from North America and Europe but in
greater proportion in Asian patients—are associated with a
high likelihood of objective response to both gefitinib11–14
and erlotinib.13,14 In addition to demonstrating an association
with race, recent studies have shown that the mutations are
more often seen in the other clinical subgroups that have been
associated with a heightened probability of response and
clinical benefit, such as women,15,16 patients with adenocar-
cinomas,15,16 and never-smokers.15–17 However, these muta-
tions have not been clearly associated with improved survival
in trials of EGFR TKIs and have yielded inconsistent re-
sults.18–20 There has also been a lack of consensus on the
predictive and prognostic value of EGFR immunohistochem-
istry (IHC) and/or fluorescence in situ hybridization (FISH).
Some studies supporting a strong association between sur-
vival and/or response and EGFR overexpression by one or
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both of these techniques,19,20 whereas others have failed to
demonstrate such an association.11,21 The population of never-
smokers comprises approximately 10% to 15% of those
diagnosed with lung cancer and has recently emerged as a
distinct clinical entity with unique epidemiology, natural
history, and response to treatment.22 Never-smokers almost
exclusively develop NSCLC (in particular adenocarcinomas
with or without bronchoalveolar carcinoma [BAC] features),
they are disproportionately female and often older than other
patients at diagnosis. Early studies of underlying tumor biol-
ogy demonstrated that lung adenocarcinomas in nonsmokers
are genetically much simpler than those that arise in smok-
ers23 and are extremely unlikely to harbor k-ras mutations24
but more likely than other lung cancers to possess HER-2/neu
mutations.25 Pao and colleagues14 showed that never-smokers
are especially likely to have tumors with an activating muta-
tion of the EGFR and that these mutations are associated with
a strong possibility of objective response to EGFR TKIs
gefitinib and erlotinib. As already noted, a particularly high
proportion of EGFR mutation-positive tumors has consis-
tently been seen among never-smokers by United States-
based investigators17 and in Asian populations.15,16 Thus,
smoking status has consistently emerged as a clinical variable
predictive of significant clinical benefit with these agents in
therapeutic trials. As previously noted, the never-smoker
population derived the largest survival benefit among the
clinical subsets on the BR.21 trial of erlotinib versus
placebo as monotherapy for previously treated patients with
NSCLC.26 In addition, a recent post hoc analysis of data from
the BR.21 trial demonstrated that never-smoking status was
more predictive of survival benefit from erlotinib than EGFR
expression by IHC in a multivariate model.27 Although the
overall survival results of the ISEL trial were negative, the
study demonstrated a significant benefit in never-smokers.28
As previously observed, the never-smoker subset in the
TRIBUTE trial (i.e., first-line chemotherapy and concurrent
erlotinib)10 showed significantly better overall and progres-
sion-free survival compared with chemotherapy alone in an
otherwise negative trial. Finally, in EGFR TKI monotherapy
trials29 of the BAC population, gefitinib was associated with
significantly superior survival among lifelong non-smokers
compared with former or current smokers, whereas the re-
sponse rate in a similar trial of erlotinib in BAC30 was more
than twofold higher in never-smokers compared with smok-
ers. At this point, erlotinib treatment of patients with BAC or
no smoking history in the first-line setting has a compelling
rationale but requires additional study before it can be rou-
tinely recommended. Erlotinib as single agent has been tested
as first-line therapy in 53 patients affected by advanced
NSCLC.31 This treatment induced a 23% response rate and a
55% non-progression rate at 6 weeks; median time to pro-
gression was 3 months, and median survival was 13 months.
Such results can be considered encouraging in the first-line
setting. Therefore, the activity of erlotinib as single agent,
given in first-line therapy of NSCLC patients, provides the
rationale of the TORCH study. This is a phase 3 protocol
investigating whether erlotinib as first-line therapy until pro-
gression followed by chemotherapy with cisplatin and gem-
citabine (PG) will be inferior to the standard arm, consisting
of first-line PG for 6 cycles, followed at progression by
erlotinib until progression in terms of overall survival.
Monoclonal antibodies targeting EGFR, such as cetux-
imab and panitumumab, have not been studied extensively in
NSCLC. A randomized phase 2 trial by Rosell and col-
leagues32 administered first-line cisplatin/vinorelbine alone or
in combination with cetuximab. Although there was a sug-
gestion of a potential efficacy benefit with the addition of
cetuximab from this trial, as well as encouraging results from
other trials combining first-line chemotherapy doublets with
cetuximab,33,34 the merit of this approach will ultimately be
determined by the randomized phase 3 FLEX trial. In this
trial, cisplatin/vinorelbine with or without cetuximab will be
administered to previously untreated patients with advanced
NSCLC. Another prospective randomized phase 3 trial is
being conducted in the second-line setting; patients may
receive standard chemotherapy (previously, randomization to
docetaxel or pemetrexed, now amended to pemetrexed only)
with or without cetuximab.
The Southwest Oncology Group (SWOG) reported the
results of SWOG 0342,35 a randomized phase 2 study of
cetuximab administered concurrently with first-line carboplatin/
paclitaxel and followed by maintenance cetuximab in non-
progressors after four cycles of chemotherapy, or an alterna-
tive approach of chemotherapy alone followed by sequential
maintenance therapy in non-progressors after four cycles of
the same chemotherapy. The concurrent arm with mainte-
nance had a median overall survival of 10 months, meeting
the prespecified target for further study.
Other monoclonal antibodies against EGFR, including
panitumumab and matuzumab, have also completed early
clinical trials, generally in combination with chemotherapy.
Early clinical trials have demonstrated no unexpected safety
concerns and efficacy results—findings encouraging enough
to move ahead with later clinical trials in the phase 2 and 3
settings.
Bevacizumab is an antibody to the vascular endothelial
growth factor (VEGF) ligand and has antiangiogenic activity
in multiple preclinical models and clinical settings.36 Active
in a range of solid tumors, bevacizumab has also been the
subject of considerable interest for treatment of advanced
NSCLC. A randomized phase 2 trial37 demonstrated a very
encouraging potential survival benefit, especially for the dose
of 15 mg/kg IV every 3 weeks when combined with standard
carboplatin and paclitaxel. This trial reported a concerning
risk for life-threatening or fatal hemoptysis, which was asso-
ciated with squamous-type tumors, in a minority of patients.
Consequently, the subsequent phase 3 trial with bevacizumab
excluded patients with squamous tumors, as well as those
with prior hemoptysis, brain tumors, and/or those patients on
therapeutic anticoagulation because of concerns about the
potential risk of clinical bleeding in these settings.
In contrast to the negative findings from studies of
chemotherapy and EGFR-based therapies, the ECOG 4599
trial38 of carboplatin/paclitaxel along with either the anti-
VEGF antibody bevacizumab or placebo reported a survival
benefit in the first-line NSCLC setting. There was a signifi-
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cant benefit for the combination of carboplatin/paclitaxel
every 3 weeks for up to six cycles, along with bevacizumab
15 mg/kg on the same schedule, compared with placebo.
Bevacizumab or placebo was continued until disease progres-
sion. Despite the eligibility restrictions already described,
there were a few cases of fatal hemoptysis or other bleeding
complications in bevacizumab-treated patients, although at
about half the rate reported in the phase 2 study. The inves-
tigators concluded that the combination of carboplatin/pacli-
taxel/bevacizumab should be the new standard first-line ap-
proach within ECOG for patients with non-squamous
NSCLC, no prior hemoptysis, no brain metastases, and not
receiving therapeutic anticoagulation. The National Compre-
hensive Cancer Network now endorses the combination of
concurrent chemotherapy and bevacizumab as first-line treat-
ment for patients with advanced NSCLC, no prior chemo-
therapy, performance status of 0-2, and none of the afore-
mentioned exclusion criteria in its treatment guidelines39 for
this setting.
There are various other antiangiogenic agents in clini-
cal trials of advanced NSCLC, with several distinct mecha-
nisms of action. AZD 2171 is an oral small-molecule TKI of
the VEGF receptor that has demonstrated safety and encour-
aging activity in a phase 1 combination trial with carboplatin/
paclitaxel.40 This result has led to an ongoing phase 2/3 trial
run by NCIC (BR.24) of chemotherapy alone or in combina-
tion with AZD 2171 that will include a broad range of
advanced NSCLC patients rather than the narrower subset
identified by the E4599 eligibility criteria. Safety of this
alternative antiangiogenic strategy will be carefully moni-
tored. Other antiangiogenic agents, including soluble VEGF
receptors, are used in earlier stages of clinical trials for lung
cancer treatment. It is not clear whether the bleeding com-
plications identified in the bevacizumab trials are a class
effect or are specific to bevacizumab.
An alternative to combining two or more molecular
therapies with distinct targeted pathways is to inhibit more
than one target with a single agent. One of the agents exempli-
fying this strategy is vandetanib (AZD 6474), an orally
available tyrosine kinase that can inhibit both VEGF and
EGFR. This agent was compared in a randomized phase 2
trial with gefitinib as salvage therapy for advanced NSCLC
and showed an improved progression-free survival, although
overall survival was not superior.41 Crossover from one agent
to the other was permitted after progression on the initially
assigned agent. Another randomized phase 2 trial42 with 127
patients compared second-line docetaxel alone against the
combination of docetaxel with placebo or vandetanib at 100
mg or 300 mg daily. Combination with the 100-mg dose was
associated with a strong trend toward improved progression-
free survival (12 vs 18.7 weeks, HR  0.64, p  0.074), but
there was no difference in overall survival (13 months in
both). No improvements were noticed when vandetanib was
administered at a higher dose of 300 mg daily. There is no
clear explanation for the lack of a dose-response relationship,
but the unfavorable results may have emerged from a detri-
mental interaction of docetaxel with EGFR inhibitory effects
that are seen only at the higher dose. Based on the favorable
results of the latter trial, a prospective randomized phase 3
trial that compares docetaxel alone with docetaxel/vandetanib
in the setting of second-line advanced NSCLC is being
initiated.
Finally, other multikinase inhibitors, such as sunitinib
and sorafenib, have been studied in single-arm trials of
patients previously treated with advanced NSCLC. Sunitinib,
which inhibits VEGFR1, 2 and 3, PDGF-alpha/beta, Ret, Kit,
and Flt3, was tested in 63 patients and had a very encouraging
response rate of 10%, a median progression-free survival of
11 weeks, and a median overall survival of 24 weeks.43 This
degree of efficacy was promising, but toxicity was high, with
considerable fatigue, myalgias, and stomatitis, as well as
bleeding complications in three patients, although the rela-
tionship between the bleeding events and sunitinib was weak
in two of these cases. Another multikinase inhibitor, sor-
afenib, which inhibits the VEGF family of receptors as well
as PDGFR-beta and RAF, was also administered in a single-
arm phase 2 trial to 51 patients as salvage therapy for
advanced NSCLC.44 Although no objective responses were
seen, 59% of patients experienced stable disease, and the
median progression-free survival was a very encouraging 12
weeks. Modest diarrhea, hand-foot syndrome, stomatitis, and
hypertension were seen, and there was one fatal bleeding
event in a patient who had not received sorafenib for a month.
A randomized phase 3 trial of carboplatin/paclitaxel with or
without sorafenib as first-line treatment of NSCLC is cur-
rently being initiated.
CONCLUSIONS
EGFR TKI therapy, such as erlotinib, has produced an
overall survival benefit in the salvage setting and has led to
such consistent and profound improvements in the clinical
outcomes of never-smokers, patients with BAC, and patients
who have tumors with EGFR mutations or gene amplification
that first-line use is being actively studied and considered a
strong possibility outside the trial setting. We await results of
other agents targeting the EGFR axis in first-line and salvage
treatment. Antiangiogenic therapy with bevacizumab has
demonstrated a survival benefit in first-line therapy and is
being actively studied with multiple chemotherapy combina-
tions, as well as other targeted therapies. Many other targeted
therapies against these pathways, as well as very distinct
mechanisms of action, remain in clinical testing but provide
hope that we will continue to see ongoing evolutionary
improvements in clinical outcomes in advanced NSCLC and
a growing armamentarium of new options for this setting.
Targeted therapies are now being integrated with standard
chemotherapy as single agents and in combination with each
other to provide survival benefits beyond what we have been
able to achieve with chemotherapy so far, or as a less toxic
alternative to chemotherapy-based approaches.
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